Troponin I is an independent predictor of cardiovascular events and mortality in haemodialysis patients

• Verfasst von: Tydén, Maria [VerfasserIn]
• Verfasst von: Westerlund, Magnus E [VerfasserIn]
• Verfasst von: Duarte, Kevin [VerfasserIn]
• Verfasst von: Eriksson, Niclas [VerfasserIn]
• Verfasst von: Girerd, Nicolas [VerfasserIn]
• Verfasst von: Krämer, Bernhard [VerfasserIn]
• Verfasst von: März, Winfried [VerfasserIn]
• Verfasst von: Rossignol, Patrick [VerfasserIn]
• Verfasst von: Scharnagl, Hubert [VerfasserIn]
• Verfasst von: Soveri, Inga [VerfasserIn]
• Verfasst von: Svensson, Maria K [VerfasserIn]
• Verfasst von: Zannad, Faiez [VerfasserIn]
• Verfasst von: Fellström, Bengt [VerfasserIn]
• Titel: Troponin I is an independent predictor of cardiovascular events and mortality in haemodialysis patients
• Verf.angabe: Maria Tydén, Magnus E Westerlund, Kevin Duarte, Niclas Eriksson, Nicolas Girerd, Bernhard K Krämer, Winfried März, Patrick Rossignol, Hubert Scharnagl, Inga Soveri, Maria K Svensson, Faiez Zannad and Bengt Fellström
• E-Jahr: 2025
• Jahr: April 2025
• Umfang: 10 S.
• Illustrationen: Diagramme
• Fussnoten: Online veröffentlicht: 11. Februar 2025 ; Gesehen am 01.07.2025
• Titel Quelle: Enthalten in: Clinical kidney journal
• Ort Quelle: Oxford : Oxford Univ. Press, 2012
• Jahr Quelle: 2025
• Band/Heft Quelle: 18(2025), 4 vom: Apr., Artikel-ID sfaf047, Seite 1-10
• ISSN Quelle: 2048-8513
• DOI: doi:10.1093/ckj/sfaf047
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1929401256

Abstract

Patients with end-stage kidney disease (ESKD) undergoing haemodialysis (HD) have a high risk of cardiovascular (CV) events. This study evaluated troponin I (hs-cTnI) as a predictor of major adverse cardiac events (MACEs), CV death and all-cause death.The AURORA trial, a multicentre, randomized, double-blind trial involved 2776 HD patients comparing rosuvastatin with placebo. No significant effect was found on the composite primary endpoint of CV death, non-fatal myocardial infarction or non-fatal stroke. In this post hoc analysis, we analysed the association between baseline hs-cTnI and outcomes using Cox regression analyses. We adjusted for multiple background factors and available biomarkers. Hs-cTnI was log2-transformed and modelled using a four-knot restricted cubic spline. Variables were ordered by their importance in the models using χ2 value minus degrees of freedom.Baseline median hs-cTnI was 17.3 pg/mL. During follow-up, 734 MACEs, 598 CV deaths, and 1094 total deaths occurred. Patients in the upper quartile of hs-cTnI (>32.6 pg/mL) had significantly higher risk of MACEs [hazard ratio (HR) 1.92; 95% confidence interval (CI) 1.57-2.35], CV death (HR 2.12; 95% CI 1.69-2.66), all-cause death (HR 1.84; 95% CI 1.55-2.17) and non-CV death (HR 1.59; 95% CI 1.23-2.05) after full adjustment compared with those in the lowest quartile (<10.1 pg/mL). Hs-cTnI was identified as the strongest predictor for MACEs, CV death, and all-cause death, but not for non-CV death.Baseline hs-cTnI is a strong and independent predictor for MACEs and death in patients with ESKD undergoing haemodialysis.